Intelerad Medical Systems announced a partnership that will allow Apollo to resell Intelerad’s industry-leading medical imaging platform, IntelePACS.
“Apollo has a strong reputation for delivering high-quality clinical multi-media workflow management solutions,” said Christian Bazinet, Chief Operating Officer, Intelerad. “By adding IntelePACS to their product portfolio, they will be able to provide customers with industry-leading solutions that drive both quality and productivity in medical imaging environments.”
Founded in 1993, Apollo is a healthcare IT company with a reputation for delivering quality clinical multi-media workflow management solutions. Apollo’s arcc (autonomous repository for clinical content) solution provides clinical workflow and secure access and management of all clinical multimedia content across the enterprise. Its customer base includes leading academic centers, regional medical networks, commercial laboratories, and community hospitals across the U.S. and Canada.
With IntelePACS, Apollo will gain a highly-scalable medical imaging platform with a proven reputation in hospitals, imaging centers and teleradiology organizations. In addition to offering high levels of interoperability, Intelerad’s highly-intuitive solutions are renowned for streamlining workflows to optimize resource utilization; achieving a universal view of patient images and information, whether it is stored locally or in a third party HIS, RIS, PACS or VNA; and simplifying and enhancing IT infrastructure through flexible modules that enable cross-enterprise integration, collaboration, visualization, and more.
“For years, Apollo has leveraged clinical knowledge and experience into developing innovative and leading-edge technology solutions,” said Mark Newburger, CEO, Apollo. “Through our partnership with Intelerad and adding IntelePACS to Apollo’s arcc, we look forward to providing our clients a robust medical imaging platform and industry-leading workflow solutions.”
For more information: www.intelerad.com.
October 30, 2025 
